A Gene Hunting Study for Familial Papillary Thyroid Cancer

Overview

The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). Papillary thyroid cancer is a type of cancer that shows high heritability. However, the specific genetic factors that cause an increased risk have been elusive.

Full Title of Study: “A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2023

Detailed Description

The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). This can be accomplished in several ways, including loss of heterozygosity studies as well as comparative gene expression analysis. When possible, linkage analysis on families with multiple individuals affected with PTC may also help identify the putative gene(s). Study participants will be asked to: 1. Complete family history and medical history questionnaires 2. Sign a medical record release so that thyroid cancer pathology reports can be obtained 3. Supply a blood or saliva sample for genetic studies 4. Provide study related information to family members who are needed for family studies

Clinical Trial Outcome Measures

Primary Measures

  • Genetic variants associated with familial papillary thyroid cancer as assessed by multiple genetic testing methodologies
    • Time Frame: Up to 5 years
    • Variants will be assessed for segregation within families, expression in the normal thyroid and/or thyroid cancer, and functional significance

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with a diagnosis of PTC and a family history of PTC in 3 or more living relatives – Affected and unaffected family members of the proband* – For familial cases (families with 4 or more cases of PTC), participation will be offered to all living family members with PTC or benign thyroid disease as well as selected unaffected first and second degree relatives. Participation may also be offered to spouses when needed for analyzing parent/offspring samples. Exclusion Criteria:

  • Known germline predisposition (ex: pathogenic PTEN variant) – Non-English speaking

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ohio State University Comprehensive Cancer Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Matthew Ringel, Principal Investigator – Ohio State University Comprehensive Cancer Center
  • Overall Official(s)
    • Matthew Ringel, MD, Principal Investigator, Ohio State University Comprehensive Cancer Center
  • Overall Contact(s)
    • Ohio State University Comprehensive Cancer Center, 614-293-5066, OSUCCCClinicaltrials@osumc.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.